Treosulfan
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Oral, IV |
| ATC code | L01AB02 (WHO) |
| Identifiers | |
| |
| Synonyms | 1,2,3,4-Butanetetrol, 1,4-dimethanesulfonate, Threitol 1,4-dimethanesulfonate, Threitol 1,4-bismethanesulfonate; L-Threitol 1,4-bis(methanesulfonate); Ovastat; Threosulphan; Treosulphan; Tresulfan |
| CAS Number |
299-75-2  |
| PubChem (CID) | 9296 |
| UNII |
CO61ER3EPI  |
| ECHA InfoCard | 100.005.529 |
| Chemical and physical data | |
| Formula | C6H14O8S2 |
| Molar mass | 278.30056 g·mol−1 |
| Melting point | 101.5 to 105 °C (214.7 to 221.0 °F) |
| (what is this?) (verify) | |
Treosulfan is a substance that is being studied in the treatment of cancer.[1] It belongs to the family of drugs called alkylating agents. It has been used mainly as a substitute of busulfan in frail patients, as the side effects and toxicity are supposedly less severe.
References
- ↑ Schmittel A, Schmidt-Hieber M, Martus P, et al. (December 2006). "A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma". Ann. Oncol. 17 (12): 1826–9. doi:10.1093/annonc/mdl309. PMID 16971664.
External links
- Treosulfan entry in the public domain NCI Dictionary of Cancer Terms
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
This article is issued from Wikipedia - version of the 9/2/2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.